Table 4. Subgroup analysis of plasma CZP concentration ([CZP]) at Week 24 (observed data) in HIKARI.

						LDA
Groups	[CZP] Subgroup no.	[CZP] (μg/mL)	N	%Group	[CZP] geometric mean (μg/mL)	N	%Subgroup
LD (n = 103 a )	1	<12.0	21	20.4	4.6	7	33.3
	2	≤12.0, <26.6	27	26.2	19.2	9	33.3
	3	≤26.6, <38.1	32	31.1	31.8	12	37.5
	4	≤38.1	23	22.3	51.5	12	52.2
	No-LD (n = 87 a )	1	<12.0	26	29.9	3.8	4	15.4
2		≤12.0, <26.6	21	24.1	19.2	7	33.3
3		≤26.6, <38.1	15	17.2	31.4	2	13.3
4		≤38.1	25	28.7	52.9	8	32.0

CZP-ADAb, antibodies to CZP; LD, loading dose; LDA, low disease activity.

^a Patients for whom data are available.